CD96 and lymphoma: Oncomine data showed increased levels of CD96 in brain, breast, and kidney cancers and leukemia relative to normal tissues, while in several datasets, CD96 levels were lower in breast, colorectal and gastric cancers, as well as in leukemia, lymphoma, melanoma, and sarcoma.